Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
Targeted cancer therapy allows the delivery of therapeutic agents to cancer cells without incurring undesirable side effects on the neighboring healthy tissues. Over the past decade, there has been an increasing interest in the development of advanced cancer therapeutics using targeted nanoparticles. Here we describe the preparation of drug-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D: ,L: -lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A10 2-fluoropyrimidine ribonucleic acid aptamers that recognize the extracellular domain of prostate-specific membrane antigen (PSMA), a well-characterized antigen expressed on the surface of prostate cancer cells. We show that the self-assembled nanoparticles can selectively bind to PSMA-targeted prostate cancer cells in vitro and in vivo. This formulation method may contribute to the development of highly selective and effective cancer therapeutic and diagnostic devices.
Gu
Frank
F
Harvard-MIT Center for Cancer Nanotechnology Excellence, Massachusetts Institute of Technology, Cambridge, MA, USA.
Langer
Robert
R
Farokhzad
Omid C
OC
D000818:Animals; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism; D052157:Aptamers, Nucleotide / Q000008:administration & dosage / Q000235:genetics; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D043425:Glutamate Carboxypeptidase II / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*; D036103:Nanotechnology; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D014183:Transplantation, Heterologous
D000954:Antigens, Surface; D052157:Aptamers, Nucleotide; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II